The PrognoScan survival analysis also revealed significant differences in OS between the high and low expression groups of KCTD5 in ovarian cancer (P = 0.002, HR = 5.68), follicular lymphoma (P = 0.013, HR = 0.65), colorectal cancer (P = 0.025, HR = 0.24), and melanoma (P = 0.027, HR = 0.39) (Fig. 4B). This evidence concerns the gene KCTD5 and ovarian cancer.